BR112023001487A2 - Método para tratar um câncer, método para estimular células imunes, kit farmacêutico e uso do kit farmacêutico - Google Patents
Método para tratar um câncer, método para estimular células imunes, kit farmacêutico e uso do kit farmacêuticoInfo
- Publication number
- BR112023001487A2 BR112023001487A2 BR112023001487A BR112023001487A BR112023001487A2 BR 112023001487 A2 BR112023001487 A2 BR 112023001487A2 BR 112023001487 A BR112023001487 A BR 112023001487A BR 112023001487 A BR112023001487 A BR 112023001487A BR 112023001487 A2 BR112023001487 A2 BR 112023001487A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical kit
- cancer
- treatment
- immune cells
- stimulating immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063057054P | 2020-07-27 | 2020-07-27 | |
| US202163177036P | 2021-04-20 | 2021-04-20 | |
| US202163219066P | 2021-07-07 | 2021-07-07 | |
| PCT/US2021/042901 WO2022026306A1 (en) | 2020-07-27 | 2021-07-23 | Methods for the use of a pd-1 x ctla-4 bispecific molecule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001487A2 true BR112023001487A2 (pt) | 2023-02-14 |
Family
ID=80036053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001487A BR112023001487A2 (pt) | 2020-07-27 | 2021-07-23 | Método para tratar um câncer, método para estimular células imunes, kit farmacêutico e uso do kit farmacêutico |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230312756A1 (https=) |
| EP (1) | EP4188961A4 (https=) |
| JP (1) | JP2023536086A (https=) |
| KR (1) | KR20230042038A (https=) |
| CN (1) | CN116134053A (https=) |
| AU (1) | AU2021316192A1 (https=) |
| BR (1) | BR112023001487A2 (https=) |
| CA (1) | CA3189926A1 (https=) |
| IL (1) | IL300166A (https=) |
| MX (1) | MX2023001111A (https=) |
| TW (1) | TW202220691A (https=) |
| WO (1) | WO2022026306A1 (https=) |
| ZA (1) | ZA202300822B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120648657A (zh) * | 2024-03-08 | 2025-09-16 | 上海锦斯生物技术有限公司 | 一种修饰的溶瘤病毒及其组合物 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| IL260021B (en) * | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| JP7010854B2 (ja) * | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2019179421A1 (en) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific pd-1/ctla-4 antibody molecules |
-
2021
- 2021-07-23 TW TW110127252A patent/TW202220691A/zh unknown
- 2021-07-23 IL IL300166A patent/IL300166A/en unknown
- 2021-07-23 CN CN202180059321.7A patent/CN116134053A/zh active Pending
- 2021-07-23 BR BR112023001487A patent/BR112023001487A2/pt unknown
- 2021-07-23 JP JP2023505707A patent/JP2023536086A/ja active Pending
- 2021-07-23 WO PCT/US2021/042901 patent/WO2022026306A1/en not_active Ceased
- 2021-07-23 US US18/006,294 patent/US20230312756A1/en active Pending
- 2021-07-23 EP EP21849290.8A patent/EP4188961A4/en active Pending
- 2021-07-23 CA CA3189926A patent/CA3189926A1/en active Pending
- 2021-07-23 KR KR1020237004873A patent/KR20230042038A/ko active Pending
- 2021-07-23 AU AU2021316192A patent/AU2021316192A1/en active Pending
- 2021-07-23 MX MX2023001111A patent/MX2023001111A/es unknown
-
2023
- 2023-01-18 ZA ZA2023/00822A patent/ZA202300822B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL300166A (en) | 2023-03-01 |
| MX2023001111A (es) | 2023-03-07 |
| ZA202300822B (en) | 2023-08-30 |
| US20230312756A1 (en) | 2023-10-05 |
| EP4188961A1 (en) | 2023-06-07 |
| KR20230042038A (ko) | 2023-03-27 |
| TW202220691A (zh) | 2022-06-01 |
| CA3189926A1 (en) | 2022-02-03 |
| AU2021316192A1 (en) | 2023-02-23 |
| CN116134053A (zh) | 2023-05-16 |
| WO2022026306A1 (en) | 2022-02-03 |
| JP2023536086A (ja) | 2023-08-23 |
| EP4188961A4 (en) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022819A2 (pt) | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula | |
| MX2022002977A (es) | Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3. | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112023001956A2 (pt) | Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| WO2021133653A8 (en) | Therapy for the treatment of cancer | |
| BR112023006024A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112023002150A2 (pt) | Anticorpos direcionando egfr e uso dos mesmos | |
| BR112023001487A2 (pt) | Método para tratar um câncer, método para estimular células imunes, kit farmacêutico e uso do kit farmacêutico | |
| BR112022015572A2 (pt) | Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| BR112022022418A2 (pt) | Anticorpos de alvejamento de clec12a e uso dos mesmos | |
| BR112022021447A2 (pt) | Moléculas de ligação para o tratamento de câncer | |
| BR112023021177A2 (pt) | Anticorpo, composição farmacêutica, uso do anticorpo, método para prevenir e/ou tratar um tumor, kit, formulação unitária, método para prevenir ou tratar um câncer ou tumor e unidade de dose única | |
| BR112022022900A2 (pt) | Método de tratamento de um câncer | |
| WO2022119830A8 (en) | Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy | |
| MX2021009189A (es) | Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer. | |
| BR112023009665A2 (pt) | Compostos e composições de molécula pequena | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica |